About Proniras
Proniras is a company based in Seattle (United States) founded in 2018. Proniras has raised $11.23 million across 3 funding rounds from investors including Arch Venture Partners, Accelerator and Watson Fund. The company has 2 employees. Proniras offers products and services including Tezampanel and Novel Treatment for Opiate Withdrawal. Proniras operates in a competitive market with competitors including Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Edge Therapeutics, among others.
- Headquarter Seattle, United States
- Employees 2
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website proniras.com
- Social LinkedIn
- Legal Name Proniras Corporation
- Total Equity Funding$11.23M (USD)
in 3 rounds
- Latest Funding Round$6.93M (USD), Series B
Dec 2023
- InvestorsArch Venture Partners
& 4 more
- Employee Count2
Products & Services of Proniras
Proniras offers a comprehensive portfolio of products and services, including Tezampanel and Novel Treatment for Opiate Withdrawal.
Treatment for seizure disorders through development programs
Phase 1 study for addressing opiate withdrawal symptoms
Funding Insights of Proniras
Proniras has successfully raised a total of $11.23M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $6.93 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.23M
- Total Rounds 3
- Last Round Series B — $6.93M
- First Round $4.3M
(Jul 2019)
- Investors Count 5
All 3 funding rounds of Proniras with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $6.93M | Series B | – | Accelerator Life Science Partners, Arch Venture Partners | |
| Sep 2020 | $12.3M | Grant | – | – | |
| Jul 2019 | $4.3M | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Proniras
Proniras has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Arch Venture Partners, Accelerator and Watson Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital services are offered for early-stage biotech companies. | – | acceleratorlsp.com | Seattle, United States | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Early-stage venture capital is provided to US companies across sectors. | – | wrfseattle.org | Seattle, United States | |
A healthcare venture capital fund focused on early-stage investments. | – | watsonfund.com | Seattle, United States | |
Scientific research on drug use and addiction is supported. | – | drugabuse.gov | United States |
Investor details for Proniras
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Proniras
5 people are tracked at Proniras (3 in leadership, 2 in board & advisors); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Christopher Toombs | CoFounder & Chief Scientific Officer | Leadership |
Thong Q. Le | President & CEO | Leadership |
Lindsay Rayle | VP, Finance | Leadership |
Alice Ly | Director | Board & advisors |
Steven Gillis | Director | Board & advisors |
Complete people profiles for Proniras
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Proniras
3 dated milestones of Proniras across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Proniras is founded.
- Funding First funding round of $4.3M.
- Funding Latest funding round, Series B, of $6.9M.
Competitors of Proniras
Proniras operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Edge Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| neuraptive.com | 2016 | Lafayette, United States | $12.5M | – | Therapeutic solution for the repair of cut and crushed peripheral nerves. | |
| verinos-pharma.com | 1998 | Wurzburg, Germany | $62.7M | – | Developer of therapeutics for retina and brain diseases | |
| ischemix.com | 2006 | Grafton, United States | $6.6M | – | Developer of cytoprotective therapy for traumatic brain injury | |
| edgetherapeutics.com | 2009 | New Providence, United States | $164.73M | 26 | Novel therapies for acute neurological conditions are developed and commercialized. | |
| neurexistherapeutics.com | 2020 | Aurora, United States | $605,000 | – | Neuroprotective therapeutic peptides are developed for brain disorder treatment. | |
| nervgen.com | 2016 | Vancouver, Canada | – | – | Nerve damage treatments are developed by inhibiting PTPσ receptor. | |
| hiteck.com.cn | 2001 | Wuhan, China | – | – | Biological products including growth factor injections are developed and manufactured. |
Detailed competitors of Proniras
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proniras
Complete news archive for Proniras
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Proniras
10 companies that operate in the same segment as Proniras (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Proniras
Proniras was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Proniras is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Proniras is a funded company, having raised a total of $11.23M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.3M, raised on Jul 2019.
Proniras has 2 employees.
Proniras was founded in 2018 and is located in Seattle, United States. Small molecules are being developed by the company as medical countermeasures against seizures and brain injury from organophosphorus nerve agents. The lead candidate, tezampanel, functions as an AMPAkainate receptor antagonist and is advanced in the preclinical stage for parenteral administration. Development status was reported as preclinical in February 2019.
Proniras's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
Proniras offers Tezampanel and Novel Treatment for Opiate Withdrawal.
Proniras has 5 investors. Key investors include Arch Venture Partners, Accelerator, Watson Fund, Washington Research Foundation, and National Institute on Drug Abuse.
Proniras operates through Proniras Corporation.